The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
Open accessAbstract
Familial defective apolipoprotein B100 (FDB) is caused by a mutation of apo-B100 (R3500Q) that disrupts the receptor binding of low density lipoproteins (LDL), which leads to hypercholesterolemia and premature atherosclerosis. In this study, mutant forms of human apo-B were expressed in transgenic mice, and the resulting human recombinant LDL were purified and tested for their receptor-binding activity. Site-directed mutagenesis and other evidence indicated that Site B (amino acids 3,359-3,369) binds to the LDL receptor and that arginine-3,500 is not directly involved in receptor binding. The carboxyl-terminal 20% of apo-B100 is necessary for the R3500Q mutation to disrupt receptor binding, since removal of the carboxyl terminus in FDB LDL results in normal receptor-binding activity. Similarly, removal of the carboxyl terminus of apo-B100 on receptor-inactive VLDL dramatically increases apo-B-mediated receptor-binding activity. We propose that the carboxyl terminus normally functions to inhibit the interaction of apo-B100 VLDL with the LDL receptor, but after the conversion of triglyceride-rich VLDL to smaller cholesterol-rich LDL, arginine-3,500 interacts with the carboxyl terminus, permitting normal interaction between LDL and its receptor. Moreover, the loss of arginine at this site destabilizes this interaction, resulting in receptor-binding defective LDL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 2×
“Furthermore, Site B has clusters of basic amino acids known to be important for binding to the LDL receptor and is extremely similar to the site on apo-E that binds to the LDL receptor (13, 14).”
BackgroundLipoprotein-receptor interactions
Innerarity, T. L., Pitas, R. E., & Mahley, R. W. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29091-6 · Cited by 186
Self-citation
Cited by
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationSubendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
“The first transgenic mouse line expressed human recombinant control LD”
BackgroundSelf-citationDiabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Structure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., De Loof, H., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 522
Hevonoja, T., Pentikäinen, M. O., Hyvönen, M. T., Kovanen, P. T., & Ala-Korpela, M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00123-2 · Cited by 436
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
THE MAMMALIAN LOW-DENSITY LIPOPROTEIN RECEPTOR FAMILY
Hussain, M. M., Strickland, D. K., & Bakillah, A. (1999) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.19.1.141 · Cited by 377
Camejo, G., Hurt-Camejo, E., Wiklund, O., & Bondjers, G. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00107-5 · Cited by 334
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Self-citationOLOFSSON, S. ‐., & BORÈN, J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01556.x · Cited by 330
Borén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2265 · Cited by 320
Self-citationSTRUCTURE AND PHYSIOLOGIC FUNCTION OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR
Jeon, H., & Blacklow, S. C. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133354 · Cited by 310
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
Lipid droplets as dynamic organelles connecting storage and efflux of lipids
Olofsson, S.-O., Boström, P., Andersson, L., Rutberg, M., Perman, J., & Borén, J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.08.001 · Cited by 265
Lipid disorders and mutations in the APOB gene
Whitfield, A. J., Barrett, P. H. R., van Bockxmeer, F. M., & Burnett, J. R. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038026 · Cited by 243
Fisher, C., Beglova, N., & Blacklow, S. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.021 · Cited by 185
“First, a number of known ligands for LDLR family proteins are highly basic, with clusters of basic residues on apolipoprotein E (ApoE) and apolipoprotein B implicated in binding to the LDLR (Boren et al., 1998; Knott et al., 1985; Lalazar et al., 1988; Weisgraber et al., 1983).”
BackgroundKosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
“Upon reduction in size due to lipolysis, a conformational change in the C terminus of apoB100 unmasks the LDLR binding site (46).”
BackgroundBenn, M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.004 · Cited by 119
Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism
Hooper, A. J., van Bockxmeer, F. M., & Burnett, J. R. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295113 · Cited by 89
Blasiole, D. A., Oler, A. T., & Attie, A. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710457200 · Cited by 65
Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor
Reimund, M., Dearborn, A. D., Graziano, G., Lei, H., Ciancone, A. M., Kumar, A., Holewinski, R., Neufeld, E. B., O’Reilly, F. J., Remaley, A. T., et al. (2025) · Nature · doi:10.1038/s41586-024-08223-0 · Cited by 63
Gillian-Daniel, D. L., Bates, P. W., Tebon, A., & Attie, A. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072557199 · Cited by 61
The structure of apolipoprotein B100 from human low-density lipoprotein
Berndsen, Z. T., & Cassidy, C. K. (2025) · Nature · doi:10.1038/s41586-024-08467-w · Cited by 43
Tran-Lundmark, K., Tran, P.-K., Paulsson-Berne, G., Fridén, V., Soininen, R., Tryggvason, K., Wight, T. N., Kinsella, M. G., Borén, J., & Hedin, U. (2008) · Circulation Research · doi:10.1161/circresaha.107.172833 · Cited by 39
Self-citation
Metadata
- Authors
- Boren, J., Lee, I., Zhu, W., Arnold, K., Taylor, S., & Innerarity, T. L.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-03-01
- Volume
- 101
- Issue
- 5
- Pages
- 1084-1093
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2081922902
- Cited by
- 234
- References
- 2
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.